Who Paid My Doc
Ryzumvi
Drug Pharmacologically-induced mydriasis
NDC 83368-075-30
General payments
$708,988
Research payments
$5,677,214
Through program year 2025, $708,988 in general payments and $5,677,214 in research payments were reported against Ryzumvi (Pharmacologically-induced mydriasis).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $561,504 | 3,829 |
| 2025 | Research | $5,677,214 | 589 |
| 2024 | General | $147,484 | 5,064 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 28 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
8,893 general · 589 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.